Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
New England Journal of Medicine.
Times cited: 551
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study.
Annals of Oncology.
Times cited: 213